DOCSLIB.ORG

ER Alpha Binding by Transcription Factors NFIB and YBX1 Enables FGFR2 Signalling to Modulate Estrogen Responsiveness in Breast Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ER Alpha Binding by Transcription Factors NFIB and YBX1 Enables FGFR2 Signalling to Modulate Estrogen Responsiveness in Breast Cancer Author Manuscript Published OnlineFirst on November 27, 2017; DOI: 10.1158/0008-5472.CAN-17-1153 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 ER alpha binding by transcription factors NFIB and YBX1 enables FGFR2 2 signalling to modulate estrogen responsiveness in breast cancer 3 4 Thomas M. Campbell1, Mauro A. A. Castro2, Kelin Gonçalves de Oliveira2, Bruce A. J. 5 Ponder1 and Kerstin B. Meyer1,3* 6 7 *Corresponding author: [email protected] 8 1Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing 9 Centre, Robinson Way, Cambridge CB2 0RE, UK. 10 2Bioinformatics and Systems Biology Lab, Federal University of Paraná (UFPR), 11 Polytechnic Center, Rua Alcides Vieira Arcoverde, 1225 Curitiba, PR 81520-260, 12 Brazil. 13 3Current address: Wellcome Trust Sanger Institute, Wellcome Genome Campus, 14 Hinxton, Cambridge CB10 1SA, UK. 15 [email protected] 16 [email protected] 17 [email protected] 18 [email protected] 19 [email protected] 20 21 Running title: NFIB and YBX1 regulate ESR1 in breast cancer 22 5 keywords: Breast cancer, ESR1, NFIB, YBX1, FGFR2 1 Downloaded from cancerres.aacrjournals.org on September 24, 2021. © 2017 American Association for Cancer Research. Author Manuscript Published OnlineFirst on November 27, 2017; DOI: 10.1158/0008-5472.CAN-17-1153 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 23 Abstract 24 Two opposing clusters of transcription factors (TF) have been associated with the 25 differential risks of estrogen receptor positive or negative breast cancers, but the 26 mechanisms underlying the opposing functions of the two clusters are undefined. In 27 this study, we identified NFIB and YBX1 as novel interactors of the estrogen receptor 28 (ESR1). NFIB and YBX1 are both risk TF associated with progression of ESR1-negative 29 disease. Notably, they both interacted with the ESR1-FOXA1 complex and inhibited 30 the transactivational potential of ESR1. Moreover, signaling through FGFR2, a known 31 risk factor in breast cancer development, augmented these interactions and further 32 repressed ESR1 target gene expression. We therefore show that members of two 33 opposing clusters of risk associated with ESR1 positive and negative breast cancer 34 can physically interact. We postulate that this interaction forms a toggle between 35 two developmental pathways affected by FGFR2 signaling, possibly offering a 36 junction to exploit therapeutically. 37 2 Downloaded from cancerres.aacrjournals.org on September 24, 2021. © 2017 American Association for Cancer Research. Author Manuscript Published OnlineFirst on November 27, 2017; DOI: 10.1158/0008-5472.CAN-17-1153 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 38 Introduction 39 The estrogen receptor (ESR1) is the key driver and therapeutic target of breast 40 cancer [1] and plays a critical role in determining the risk of developing this disease 41 [2-4]. Using a systems biology approach we have examined transcriptional networks 42 in breast cancer affecting ESR1 activity and have identified two distinct and opposing 43 clusters of transcription factors (TFs) associated with enhanced breast cancer risk 44 [5]. The “cluster 1” risk TFs are associated with estrogen receptor-positive (ER+) 45 breast cancer risk and comprise TFs such as ESR1, FOXA1 and GATA3 whereas the 46 “cluster 2” risk TFs appear to be associated with estrogen receptor-negative (ER-), 47 basal-like breast cancer (BLBC). Two of the TFs located in the cluster associated with 48 ER- disease are NFIB and YBX1. Here we examine the molecular mechanisms 49 underlying the opposing functions of the two groups of TFs by studying protein- 50 protein interactions between TFs and their functional consequences. We also 51 examine the effect of cell signalling, in particular by fibroblast growth factor receptor 52 2 (FGFR2), on the relative activity of the two groups of TFs. 53 The nuclear factor I (NFI) family of TFs consists of four members, NFIA, NFIB, 54 NFIC and NFIX, which can all bind DNA as homo- or heterodimers [6]. They are 55 particularly important during developmental stages [7, 8], and NFIB is crucial for 56 normal lung and brain development [9]. NFIB commonly has an increased copy 57 number in small cell lung cancer (SCLC), indicating a role as an oncogene [10]. In 58 BLBC, both copy number and expression levels of NFIB are also increased [11, 12]. In 59 addition, NFIB is important in the regulation of expression of mammary gland- 60 specific genes, specifically those associated with lactation such as Whey acidic 61 protein (WAP) and α-lactalbumin [13]. NFIB has been shown to modulate androgen 3 Downloaded from cancerres.aacrjournals.org on September 24, 2021. © 2017 American Association for Cancer Research. Author Manuscript Published OnlineFirst on November 27, 2017; DOI: 10.1158/0008-5472.CAN-17-1153 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 62 receptor (AR) target genes in prostate cancer cells via an interaction with FOXA1 [14, 63 15]. An investigation into whether similar modulation of estrogen receptor (ER) 64 occurs in the breast has yet to be carried out. 65 Y-box binding protein 1 (YBX1) is a member of a family of DNA- and RNA- 66 binding proteins with an evolutionarily ancient and conserved cold shock domain. It 67 is a multifunctional protein that certainly does not follow the classical “one protein- 68 one function” rule, but rather has disordered structure suggesting many different 69 functions [16]. It has been extensively studied in cancer and its overexpression is 70 associated with many hallmarks of the disease. It is expressed in many breast cancer 71 cell lines regardless of subtype. However, there are higher levels of phosphorylated 72 YBX1 in BLBC cell lines [17, 18]. YBX1 expression in inversely correlated with ER, PR 73 and HER2 expression and is positively correlated with the MAPK signalling cascade, a 74 pathway important in BLBC [19, 20]. YBX1 is highly expressed in 70% of BLBC cases 75 and many of its target genes are associated with a basal-like signature [18, 20]. 76 Higher expression of YBX1 correlates with poor survival, drug resistance and a high 77 rate of relapse in all subtypes [18, 19, 21-23]. Suppression of YBX1 reduces 2D cell 78 growth and growth in mammospheres [18, 20]. There is also evidence to suggest 79 that YBX1 binds ESR1 in ER+ breast cancer cell nuclei [24, 25]. 80 A locus within the second intron of the FGFR2 (fibroblast growth factor 81 receptor 2) gene is consistently identified as the genetic locus most strongly 82 associated with estrogen receptor-positive (ER+) breast cancer risk by independent 83 genome-wide association studies (GWASs) [26]. We have shown previously that the 84 top three risk single nucleotide polymorphisms (SNPs) [27, 28] act to reduce FGFR2 85 gene expression and enhance the estrogen response [29]. Increased FGFR2 4 Downloaded from cancerres.aacrjournals.org on September 24, 2021. © 2017 American Association for Cancer Research. Author Manuscript Published OnlineFirst on November 27, 2017; DOI: 10.1158/0008-5472.CAN-17-1153 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 86 stimulation repressed estrogen signalling in ER+ breast cancer cell lines. However, 87 the underlying molecular mechanism remains unclear. 88 Here, we demonstrate that two members of the cluster 2 TFs, NFIB and YBX1, 89 both physically interact with ESR1, repress its activity, and drive breast cancer cells 90 towards a less estrogen-dependent cancer phenotype. FGFR2 signalling augments 91 this interaction and subsequent repression of ESR1 target gene expression. Our 92 evidence suggests that FGFR2 has wide-ranging effects on driving breast cancer cells 93 towards a more basal-like phenotype and that inhibiting FGFR2 signalling in ER+ 94 breast cancer sensitizes cells to anti-estrogen therapies. 95 5 Downloaded from cancerres.aacrjournals.org on September 24, 2021. © 2017 American Association for Cancer Research. Author Manuscript Published OnlineFirst on November 27, 2017; DOI: 10.1158/0008-5472.CAN-17-1153 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 96 Materials and methods 97 Cell culture 98 MCF-7 human breast cancer cells and HeLa cells were cultured in DMEM (Invitrogen) 99 supplemented with 10% FBS and antibiotics. ZR751 human breast cancer cells were 100 cultured in RPMI (Invitrogen) supplemented with 10% FBS and antibiotics. SUM52PE 101 human breast cancer cells were cultured in Ham/F-12 (Invitrogen) supplemented 102 with 10% FBS, 5 g/mL insulin, 1 g/mL hydrocortisone and antibiotics. All cells were 103 maintained at 37°C, 5% CO2, obtained from the CRUK Cambridge Institute collection 104 and authenticated by STR genotyping. 105 106 Quantitative RT-PCR 107 1 g of total RNA was reverse transcribed using the High Capacity cDNA Reverse 108 Transcription Kit (Applied Biosystems) and qRT-PCR performed using cDNA obtained 109 from 10 ng of total RNA. qRT-PCR was performed using a QuantStudio6 system (Life 110 Technologies). Amplification and detection were carried out in 384-well Optical 111 Reaction Plates (Applied Biosystems) with Power SYBR Green Fast 2x qRT-PCR 112 Mastermix (Applied Biosystems). All expression data were normalised to DGUOK 113 expression. The specificity of primers (Supplementary Table 1) was confirmed 114 through generation of single peaks in a melt-curve analysis. Data analysis was 115 performed using the 2-CT method [30]. 116 117 Western immunoblotting 118 Cells were grown in 10 cm Petri dishes, washed in PBS and lysed on ice in RIPA buffer 119 with cOmplete Mini EDTA-free protease inhibitor cocktail (Roche).
Load more

Recommended publications
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
    [Show full text]
  • Identification of NFIB As Recurrent Translocation Partner Gene of HMGIC in Pleomorphic Adenomas
    Oncogene (1998) 16, 865 ± 872 1998 Stockton Press All rights reserved 0950 ± 9232/98 $12.00 Identi®cation of NFIB as recurrent translocation partner gene of HMGIC in pleomorphic adenomas Jan MW Geurts1, Eric FPM Schoenmakers1, Eva RoÈ ijer2, Anna-Karin AstroÈ m2,GoÈran Stenman2 and Wim JM van de Ven1 1Laboratory for Molecular Oncology, Center for Human Genetics, University of Leuven & Flanders Interuniversity Institute for Biotechnology, B-3000 Leuven, Belgium; 2Laboratory of Cancer Genetics, Department of Pathology, GoÈteborg University, Sahlgrenska University Hospital, S-41345 GoÈteborg, Sweden Approximately 12% of all pleomorphic adenomas of the guished, i.e. tumors with rearrangements of 8q12 or salivary glands are characterized by chromosome 12q13 ± 15. Whereas the t(3;8)(p21;q12) is the most aberrations involving the chromosome segment 12q13 ± frequently observed translocation, many dierent 15. Several chromosomes have been found as transloca- chromosome segments can act as translocation tion partners of chromosome 12, and some of these partners of both 8q12 and 12q13 ± 15 (Sandros et al., recurrently. Recently, the HMGIC gene was identi®ed as 1990; Bullerdiek et al., 1993). The short arm of the target gene aected by the 12q13 ± 15 aberrations. chromosome 9, with breakpoints in the segment Here, we report the identi®cation and characterization of 9p12 ± 24, is the preferential translocation partner of a new translocation partner gene of HMGIC in chromosome 12q13 ± 15 (Stenman et al., 1994). The pleomorphic adenomas. 3'-RACE analysis of a primary reason for the variability of the breakpoints in 9p is adenoma with an apparently normal karyotype revealed likely to be due to the limited resolution of the banding an HMGIC fusion transcript containing ectopic se- pattern in 9p12 ± 24 and 12q13 ± 15, making it almost quences derived from the human NFIB gene, previously impossible to determine the exact locations of the mapped to chromosome band 9p24.1.
    [Show full text]
  • Investigation of the Underlying Hub Genes and Molexular Pathogensis in Gastric Cancer by Integrated Bioinformatic Analyses
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.20.423656; this version posted December 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Investigation of the underlying hub genes and molexular pathogensis in gastric cancer by integrated bioinformatic analyses Basavaraj Vastrad1, Chanabasayya Vastrad*2 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India bioRxiv preprint doi: https://doi.org/10.1101/2020.12.20.423656; this version posted December 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract The high mortality rate of gastric cancer (GC) is in part due to the absence of initial disclosure of its biomarkers. The recognition of important genes associated in GC is therefore recommended to advance clinical prognosis, diagnosis and and treatment outcomes. The current investigation used the microarray dataset GSE113255 RNA seq data from the Gene Expression Omnibus database to diagnose differentially expressed genes (DEGs). Pathway and gene ontology enrichment analyses were performed, and a proteinprotein interaction network, modules, target genes - miRNA regulatory network and target genes - TF regulatory network were constructed and analyzed. Finally, validation of hub genes was performed. The 1008 DEGs identified consisted of 505 up regulated genes and 503 down regulated genes.
    [Show full text]
  • Cutting Edge: Expression of IRF8 in Gastric Epithelial Cells Confers
    Cutting Edge: Expression of IRF8 in Gastric Epithelial Cells Confers Protective Innate Immunity against Helicobacter pylori Infection This information is current as of September 27, 2021. Ming Yan, Hongsheng Wang, Jiafang Sun, Wei Liao, Peng Li, Yin Zhu, Chengfu Xu, Jungsoo Joo, Yan Sun, Sadia Abbasi, Alexander Kovalchuk, Nonghua Lv, Warren J. Leonard and Herbert C. Morse III J Immunol published online 3 February 2016 Downloaded from http://www.jimmunol.org/content/early/2016/02/02/jimmun ol.1500766 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2016/02/02/jimmunol.150076 Material 6.DCSupplemental Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 27, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published February 3, 2016, doi:10.4049/jimmunol.1500766 Th eJournal of Cutting Edge Immunology Cutting Edge: Expression of IRF8 in Gastric Epithelial Cells Confers Protective Innate Immunity against Helicobacter pylori Infection x x Ming Yan,*,1 Hongsheng Wang,†,1 Jiafang Sun,† Wei Liao,‡, Peng Li,‡, { † Yin Zhu, ChengfuXu,*JungsooJoo,*YanSun,*SadiaAbbasi,{ x Alexander Kovalchuk,† Nonghua Lv, Warren J.
    [Show full text]
  • 1714 Gene Comprehensive Cancer Panel Enriched for Clinically Actionable Genes with Additional Biologically Relevant Genes 400-500X Average Coverage on Tumor
    xO GENE PANEL 1714 gene comprehensive cancer panel enriched for clinically actionable genes with additional biologically relevant genes 400-500x average coverage on tumor Genes A-C Genes D-F Genes G-I Genes J-L AATK ATAD2B BTG1 CDH7 CREM DACH1 EPHA1 FES G6PC3 HGF IL18RAP JADE1 LMO1 ABCA1 ATF1 BTG2 CDK1 CRHR1 DACH2 EPHA2 FEV G6PD HIF1A IL1R1 JAK1 LMO2 ABCB1 ATM BTG3 CDK10 CRK DAXX EPHA3 FGF1 GAB1 HIF1AN IL1R2 JAK2 LMO7 ABCB11 ATR BTK CDK11A CRKL DBH EPHA4 FGF10 GAB2 HIST1H1E IL1RAP JAK3 LMTK2 ABCB4 ATRX BTRC CDK11B CRLF2 DCC EPHA5 FGF11 GABPA HIST1H3B IL20RA JARID2 LMTK3 ABCC1 AURKA BUB1 CDK12 CRTC1 DCUN1D1 EPHA6 FGF12 GALNT12 HIST1H4E IL20RB JAZF1 LPHN2 ABCC2 AURKB BUB1B CDK13 CRTC2 DCUN1D2 EPHA7 FGF13 GATA1 HLA-A IL21R JMJD1C LPHN3 ABCG1 AURKC BUB3 CDK14 CRTC3 DDB2 EPHA8 FGF14 GATA2 HLA-B IL22RA1 JMJD4 LPP ABCG2 AXIN1 C11orf30 CDK15 CSF1 DDIT3 EPHB1 FGF16 GATA3 HLF IL22RA2 JMJD6 LRP1B ABI1 AXIN2 CACNA1C CDK16 CSF1R DDR1 EPHB2 FGF17 GATA5 HLTF IL23R JMJD7 LRP5 ABL1 AXL CACNA1S CDK17 CSF2RA DDR2 EPHB3 FGF18 GATA6 HMGA1 IL2RA JMJD8 LRP6 ABL2 B2M CACNB2 CDK18 CSF2RB DDX3X EPHB4 FGF19 GDNF HMGA2 IL2RB JUN LRRK2 ACE BABAM1 CADM2 CDK19 CSF3R DDX5 EPHB6 FGF2 GFI1 HMGCR IL2RG JUNB LSM1 ACSL6 BACH1 CALR CDK2 CSK DDX6 EPOR FGF20 GFI1B HNF1A IL3 JUND LTK ACTA2 BACH2 CAMTA1 CDK20 CSNK1D DEK ERBB2 FGF21 GFRA4 HNF1B IL3RA JUP LYL1 ACTC1 BAG4 CAPRIN2 CDK3 CSNK1E DHFR ERBB3 FGF22 GGCX HNRNPA3 IL4R KAT2A LYN ACVR1 BAI3 CARD10 CDK4 CTCF DHH ERBB4 FGF23 GHR HOXA10 IL5RA KAT2B LZTR1 ACVR1B BAP1 CARD11 CDK5 CTCFL DIAPH1 ERCC1 FGF3 GID4 HOXA11 IL6R KAT5 ACVR2A
    [Show full text]
  • The Staurotypus Turtles and Aves Share the Same Origin of Sex Chromosomes but Evolved Different Types of Heterogametic Sex Determination
    The Staurotypus Turtles and Aves Share the Same Origin of Sex Chromosomes but Evolved Different Types of Heterogametic Sex Determination Taiki Kawagoshi1, Yoshinobu Uno1, Chizuko Nishida2, Yoichi Matsuda1,3* 1 Laboratory of Animal Genetics, Department of Applied Molecular Biosciences, Graduate School of Bioagricultural Sciences, Nagoya University, Nagoya, Japan, 2 Department of Natural History Sciences, Faculty of Science, Hokkaido University, Sapporo, Japan, 3 Avian Bioscience Research Center, Graduate School of Bioagricultural Sciences, Nagoya University, Nagoya, Japan Abstract Reptiles have a wide diversity of sex-determining mechanisms and types of sex chromosomes. Turtles exhibit temperature- dependent sex determination and genotypic sex determination, with male heterogametic (XX/XY) and female heterogametic (ZZ/ZW) sex chromosomes. Identification of sex chromosomes in many turtle species and their comparative genomic analysis are of great significance to understand the evolutionary processes of sex determination and sex chromosome differentiation in Testudines. The Mexican giant musk turtle (Staurotypus triporcatus, Kinosternidae, Testudines) and the giant musk turtle (Staurotypus salvinii) have heteromorphic XY sex chromosomes with a low degree of morphological differentiation; however, their origin and linkage group are still unknown. Cross-species chromosome painting with chromosome-specific DNA from Chinese soft-shelled turtle (Pelodiscus sinensis) revealed that the X and Y chromosomes of S. triporcatus have homology with P. sinensis chromosome 6, which corresponds to the chicken Z chromosome. We cloned cDNA fragments of S. triporcatus homologs of 16 chicken Z-linked genes and mapped them to S. triporcatus and S. salvinii chromosomes using fluorescence in situ hybridization. Sixteen genes were localized to the X and Y long arms in the same order in both species.
    [Show full text]
  • Xo GENE PANEL
    xO GENE PANEL Targeted panel of 1714 genes | Tumor DNA Coverage: 500x | RNA reads: 50 million Onco-seq panel includes clinically relevant genes and a wide array of biologically relevant genes Genes A-C Genes D-F Genes G-I Genes J-L AATK ATAD2B BTG1 CDH7 CREM DACH1 EPHA1 FES G6PC3 HGF IL18RAP JADE1 LMO1 ABCA1 ATF1 BTG2 CDK1 CRHR1 DACH2 EPHA2 FEV G6PD HIF1A IL1R1 JAK1 LMO2 ABCB1 ATM BTG3 CDK10 CRK DAXX EPHA3 FGF1 GAB1 HIF1AN IL1R2 JAK2 LMO7 ABCB11 ATR BTK CDK11A CRKL DBH EPHA4 FGF10 GAB2 HIST1H1E IL1RAP JAK3 LMTK2 ABCB4 ATRX BTRC CDK11B CRLF2 DCC EPHA5 FGF11 GABPA HIST1H3B IL20RA JARID2 LMTK3 ABCC1 AURKA BUB1 CDK12 CRTC1 DCUN1D1 EPHA6 FGF12 GALNT12 HIST1H4E IL20RB JAZF1 LPHN2 ABCC2 AURKB BUB1B CDK13 CRTC2 DCUN1D2 EPHA7 FGF13 GATA1 HLA-A IL21R JMJD1C LPHN3 ABCG1 AURKC BUB3 CDK14 CRTC3 DDB2 EPHA8 FGF14 GATA2 HLA-B IL22RA1 JMJD4 LPP ABCG2 AXIN1 C11orf30 CDK15 CSF1 DDIT3 EPHB1 FGF16 GATA3 HLF IL22RA2 JMJD6 LRP1B ABI1 AXIN2 CACNA1C CDK16 CSF1R DDR1 EPHB2 FGF17 GATA5 HLTF IL23R JMJD7 LRP5 ABL1 AXL CACNA1S CDK17 CSF2RA DDR2 EPHB3 FGF18 GATA6 HMGA1 IL2RA JMJD8 LRP6 ABL2 B2M CACNB2 CDK18 CSF2RB DDX3X EPHB4 FGF19 GDNF HMGA2 IL2RB JUN LRRK2 ACE BABAM1 CADM2 CDK19 CSF3R DDX5 EPHB6 FGF2 GFI1 HMGCR IL2RG JUNB LSM1 ACSL6 BACH1 CALR CDK2 CSK DDX6 EPOR FGF20 GFI1B HNF1A IL3 JUND LTK ACTA2 BACH2 CAMTA1 CDK20 CSNK1D DEK ERBB2 FGF21 GFRA4 HNF1B IL3RA JUP LYL1 ACTC1 BAG4 CAPRIN2 CDK3 CSNK1E DHFR ERBB3 FGF22 GGCX HNRNPA3 IL4R KAT2A LYN ACVR1 BAI3 CARD10 CDK4 CTCF DHH ERBB4 FGF23 GHR HOXA10 IL5RA KAT2B LZTR1 ACVR1B BAP1 CARD11 CDK5 CTCFL DIAPH1 ERCC1 FGF3 GID4
    [Show full text]
  • The Expression of Genes Contributing to Pancreatic Adenocarcinoma Progression Is Influenced by the Respective Environment – Sagini Et Al
    The expression of genes contributing to pancreatic adenocarcinoma progression is influenced by the respective environment – Sagini et al Supplementary Figure 1: Target genes regulated by TGM2. Figure represents 24 genes regulated by TGM2, which were obtained from Ingenuity Pathway Analysis. As indicated, 9 genes (marked red) are down-regulated by TGM2. On the contrary, 15 genes (marked red) are up-regulated by TGM2. Supplementary Table 1: Functional annotations of genes from Suit2-007 cells growing in pancreatic environment Categoriesa Diseases or p-Valuec Predicted Activation Number of genesf Functions activationd Z-scoree Annotationb Cell movement Cell movement 1,56E-11 increased 2,199 LAMB3, CEACAM6, CCL20, AGR2, MUC1, CXCL1, LAMA3, LCN2, COL17A1, CXCL8, AIF1, MMP7, CEMIP, JUP, SOD2, S100A4, PDGFA, NDRG1, SGK1, IGFBP3, DDR1, IL1A, CDKN1A, NREP, SEMA3E SERPINA3, SDC4, ALPP, CX3CL1, NFKBIA, ANXA3, CDH1, CDCP1, CRYAB, TUBB2B, FOXQ1, SLPI, F3, GRINA, ITGA2, ARPIN/C15orf38- AP3S2, SPTLC1, IL10, TSC22D3, LAMC2, TCAF1, CDH3, MX1, LEP, ZC3H12A, PMP22, IL32, FAM83H, EFNA1, PATJ, CEBPB, SERPINA5, PTK6, EPHB6, JUND, TNFSF14, ERBB3, TNFRSF25, FCAR, CXCL16, HLA-A, CEACAM1, FAT1, AHR, CSF2RA, CLDN7, MAPK13, FERMT1, TCAF2, MST1R, CD99, PTP4A2, PHLDA1, DEFB1, RHOB, TNFSF15, CD44, CSF2, SERPINB5, TGM2, SRC, ITGA6, TNC, HNRNPA2B1, RHOD, SKI, KISS1, TACSTD2, GNAI2, CXCL2, NFKB2, TAGLN2, TNF, CD74, PTPRK, STAT3, ARHGAP21, VEGFA, MYH9, SAA1, F11R, PDCD4, IQGAP1, DCN, MAPK8IP3, STC1, ADAM15, LTBP2, HOOK1, CST3, EPHA1, TIMP2, LPAR2, CORO1A, CLDN3, MYO1C,
    [Show full text]
  • Nutrition RP(3월호)-최종.Hwp
    Nutrition Research and Practice (2007), 1, 19-28 ⓒ2007 The Korean Nutrition Society and the Korean Society of Community Nutrition Transcriptome analysis and promoter sequence studies on early adipogenesis in 3T3-L1 cells* Su-jong Kim1, Ki-Hwan Lee1, Yong-Sung Lee1, Eun-Gyeng Mun2, Dae-Young Kwon3 and Youn-Soo Cha2§ 1Department of Biochemistry, College of Medicine, Hanyang University, Seoul 133-791, Korea 2Department of Food Science and Human Nutrition, Research Institute of Human Ecology, Chonbuk National University, Jeonju, Jeonbuk 561-756, Korea 3Food Function Research, Division Korea Food Research Institute, San46-1, Baekhyun-dong, Bundang-gu, Sungnam-si, Gyeonggi-do 463-746, Korea Received January 22, 2007; Revised March 2, 2007; Accepted March 5, 2007 Abstract To identify regulatory molecules which play key roles in the development of obesity, we investigated the transcriptional profiles in 3T3-L1 cells at early stage of differentiation and analyzed the promoter sequences of differentially regulated genes. One hundred and sixty-one (161) genes were found to have significant changes in expression at the 2nd day following treatment with differentiation cocktail. Among them, 86 transcripts were up-regulated and 75 transcripts were down-regulated. The 161 transcripts were classified into 10 categories according to their functional roles; cytoskeleton, cell adhesion, immune, defense response, metabolism, protein modification, protein metabolism, regulation of transcription, signal transduction and transporter. To identify transcription factors likely involved in regulating these differentially expressed genes, we analyzed the promoter sequences of up- or –down regulated genes for the presence of transcription factor binding sites (TFBSs). Based on coincidence of regulatory sites, we have identified candidate transcription factors (TFs), which include those previously known to be involved in adipogenesis (CREB, OCT-1 and c-Myc).
    [Show full text]
  • Inter-Individual Variation in Response to Estrogen and Implications for Breast Cancer Risk
    University of Massachusetts Amherst ScholarWorks@UMass Amherst Doctoral Dissertations Dissertations and Theses 5-8-2020 INTER-INDIVIDUAL VARIATION IN RESPONSE TO ESTROGEN AND IMPLICATIONS FOR BREAST CANCER RISK Amye L. Black University of Massachusetts Amherst Follow this and additional works at: https://scholarworks.umass.edu/dissertations_2 Part of the Cancer Biology Commons, and the Developmental Biology Commons Recommended Citation Black, Amye L., "INTER-INDIVIDUAL VARIATION IN RESPONSE TO ESTROGEN AND IMPLICATIONS FOR BREAST CANCER RISK" (2020). Doctoral Dissertations. 1976. https://doi.org/10.7275/gxe7-4m14 https://scholarworks.umass.edu/dissertations_2/1976 This Open Access Dissertation is brought to you for free and open access by the Dissertations and Theses at ScholarWorks@UMass Amherst. It has been accepted for inclusion in Doctoral Dissertations by an authorized administrator of ScholarWorks@UMass Amherst. For more information, please contact [email protected]. INTER-INDIVIDUAL VARIATION IN RESPONSE TO ESTROGEN AND IMPLICATIONS FOR BREAST CANCER RISK A Dissertation Presented by AMYE L. BLACK Submitted to the Graduate School of the University of Massachusetts Amherst in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY May 2020 Molecular and Cellular Biology © Copyright by Amye L. Black 2020 All Rights Reserved INTER-INDIVIDUAL VARIATION IN RESPONSE TO ESTROGEN AND IMPLICATIONS FOR BREAST CANCER RISK A Dissertation Presented by AMYE L. BLACK Approved as to style and content by: ____________________________________ D. Joseph Jerry, Chair ____________________________________ Sallie S. Schneider, Member ____________________________________ Kathleen Arcaro, Member ____________________________________ Thomas Zoeller, Member ____________________________________ Scott Garman, Director Molecular and Cellular Biology DEDICATION To my family, for their never-ending support.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0269772 A1 Califano Et Al
    US 20090269772A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0269772 A1 Califano et al. (43) Pub. Date: Oct. 29, 2009 (54) SYSTEMS AND METHODS FOR Publication Classification IDENTIFYING COMBINATIONS OF (51) Int. Cl. COMPOUNDS OF THERAPEUTIC INTEREST CI2O I/68 (2006.01) CI2O 1/02 (2006.01) (76) Inventors: Andrea Califano, New York, NY G06N 5/02 (2006.01) (US); Riccardo Dalla-Favera, New (52) U.S. Cl. ........... 435/6: 435/29: 706/54; 707/E17.014 York, NY (US); Owen A. (57) ABSTRACT O'Connor, New York, NY (US) Systems, methods, and apparatus for searching for a combi nation of compounds of therapeutic interest are provided. Correspondence Address: Cell-based assays are performed, each cell-based assay JONES DAY exposing a different sample of cells to a different compound 222 EAST 41ST ST in a plurality of compounds. From the cell-based assays, a NEW YORK, NY 10017 (US) Subset of the tested compounds is selected. For each respec tive compound in the Subset, a molecular abundance profile from cells exposed to the respective compound is measured. (21) Appl. No.: 12/432,579 Targets of transcription factors and post-translational modu lators of transcription factor activity are inferred from the (22) Filed: Apr. 29, 2009 molecular abundance profile data using information theoretic measures. This data is used to construct an interaction net Related U.S. Application Data work. Variances in edges in the interaction network are used to determine the drug activity profile of compounds in the (60) Provisional application No. 61/048.875, filed on Apr.
    [Show full text]
  • The Convergent Roles of the Nuclear Factor I Transcription Factors in Development and Cancer
    The convergent roles of the nuclear factor I transcription factors in development and cancer Kok-Siong Chen1, Jonathan W.C. Lim1, Linda J. Richards1,2*, Jens Bunt1* 1 Queensland Brain Institute, The University of Queensland, Brisbane, Australia 4072 2 The School of Biomedical Sciences, The University of Queensland, Brisbane, Australia 4072 * Corresponding authors: Jens Bunt: [email protected] and Linda J Richards: [email protected] 1 Highlights • NFI transcription factors play important roles in normal development and are associated with cancer in multiple organ systems. • NFI transcription factors are implicated in tumours that arise from cells that normally express the concordant transcription factor during development. • The role of NFI transcription factors in regulating the balance between cell proliferation and differentiation during development may be disrupted in cancer. • NFI transcription factors are context-dependent in various cancer types and can play either oncogenic or tumour-suppressive roles. 2 Abstract The nuclear factor I (NFI) transcription factors play important roles during normal development and have been associated with developmental abnormalities in humans. All four family members, NFIA, NFIB, NFIC and NFIX, have a homologous DNA binding domain and function by regulating cell proliferation and differentiation via the transcriptional control of their target genes. More recently, NFI genes have also been implicated in cancer based on genomic analyses and studies of animal models in a variety of tumours across multiple organ systems. However, the association between their functions in development and in cancer is not well described. In this review, we summarise the evidence suggesting a converging role for the NFI genes in development and cancer.
    [Show full text]